FIRSTSTRING RESEARCH INC
- Headquarters
- CHARLESTON, SC
- Founded
- 2007
- Latest Form D
- $3.2M, Apr 2010
- Total capital
- $10.9M
- Federal grants
- $7.7M
- 11 awards · 2015–2022
- Private capital raised
- $3.2M
- 1 Form D · last Apr 2010
- 199 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 13 pending · first 2015
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Evaluation of a Connexin-based Peptide for the Treatment of Diabetic Retinopathy$315K
- Federal grantHealth and Human S · Phase II · Improving marginal allograft outcomes through cell junction stabilization in transplantation$2M
- Federal grantDefense · Phase II · A novel peptide-based topical therapeutic to promote corneal regeneration and restore corneal biomechanics following blast and burn injuries$1.5M
- Federal grantHealth and Human S · Phase I · Evaluation of a Novel Connexin-Based Peptide in the Treatment of Combined Ionizing Radiation and Thermal Burn Injury$300K
- Federal grantHealth and Human S · Phase II · Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide$1.6M
- Federal grantHealth and Human S · Phase I · A Novel Scaffold to Promote Skin Regeneration$225K
- Federal grantHealth and Human S · Phase I · Evaluation of a Connexin based Peptide for the Treatment of Age Related Macular Degeneration$225K
- Private capital raisedForm D · SEC · 1st filing$3.2M
Show 4 earlier federal awards
- Federal grantHealth and Human S · Phase II · Evaluation of a Novel Connexin-Based Peptide for the Treatment of Diabetic Wounds$1M
- Federal grantHealth and Human S · Phase I · Stabilization of gap/tight junctions to ameliorate brain death induced endothelial cell injury$225K
- Federal grantDefense · Phase I · A Novel Peptide-based Topical Therapeutic to Promote Corneal Regeneration and Restore Corneal Biomechanics Following Blast and Burn Injuries$100K
- Federal grantHealth and Human S · Phase I · Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
Researcher links verified by same-company patents and grants- Gautam S. GhatnekarResearcherExecutive Officer, DirectorLinked by 1 patent · $3.3M in grants as PI
- CURTIS MOExecutive OfficerNamed in SEC Form D filings
- David Grant LeffellDirectorNamed in SEC Form D filings
- D. Grant CarwileDirectorNamed in SEC Form D filings
- Elliot S. FavusDirectorNamed in SEC Form D filings
- GRANT CARWILEDirectorNamed in SEC Form D filings
Show all 14 people
- James R. McNabDirectorNamed in SEC Form D filings
- JAMES MCNAB, JR.DirectorNamed in SEC Form D filings
- Neal Grant McConnellDirectorNamed in SEC Form D filings
- NED PAYNEDirectorNamed in SEC Form D filings
- Stephen W. SpeerDirectorNamed in SEC Form D filings
- Steven W. SpeerDirectorNamed in SEC Form D filings
- Tina Grant NovaDirectorNamed in SEC Form D filings
- Tony Grant BartshDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 14- PendingComposition And Methods For Preventing Radiation Injury And Promoting Tissue RegenerationUSPTOApplication 16486239
- PendingCompositions And Methods For Preserving Organ TransplantsUSPTOApplication 16923289
- GrantedFormulations And Methods Of Use For Alpha Connexin C-terminal (act) PeptidesUSPTOUS 9,161,984
Show all 14 patent records
- Composition And Methods For Preventing Radiation Injury And Promoting Tissue RegenerationMay 11, 2023 · Application 16486239Pending
- Compositions And Methods For Preserving Organ TransplantsJan 14, 2021 · Application 16923289Pending
- Formulations And Methods Of Use For Alpha Connexin C-terminal (act) PeptidesOct 20, 2015 · US 9,161,984Granted
- Compositions And Methods For Preserving Organ TransplantsApplication PCTUS2020041114Pending
- Compositions And Methods For Treating Complications Of Viral InfectionsApplication 63006498Pending
- Nanoparticle Formulations And Methods Of Use For Alpha Connexin C-terminal PeptidesApplication PCTUS2019050822Pending
- Compositions And Methods For Preserving Organ TransplantsApplication 62871475Pending
- Poly(lactic-co-glycolic acid) nanoparticles for controlled delivery of a peptideApplication 62730116Pending
- Composition And Methods For Preventing Radiation Injury And Promoting Tissue RegenerationApplication PCTUS2018000035Pending
- Composition And Methods For Preventing Radiation Injury And Promoting Tissue RegenerationApplication 62459924Pending
- Compositions And Methods For Treating Complications Of Viral Infections And Other Respiratory DisordersApplication PCTUS2021026224Pending
- Topical Gels Containing Alpha Connexin C-terminal (act) PeptidesApplication PCTUS2013028727Pending
- Compositions And Methods For Treating Complications Of Viral Infections And Other Respiratory DisordersApplication 63134462Pending
- Peptide Formulations And Ophthalmic Uses ThereofApplication 63104086Pending
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .